Neovacs

Founded in 1993, Neovacs is a Paris-based biotech that historically focused on its innovative Kinoid® active immunotherapy platform, designed to induce a patient's own immune system to regulate harmful cytokines. Following a judicial reorganization in 2020, the company pivoted to a hybrid model, pairing the management of its legacy pipeline with strategic investments in external biotech and medtech companies. This strategy aims to leverage internal expertise for portfolio growth while seeking to revive its core R&D programs under improved financial conditions.

The Kinoid® platform is an active immunotherapy technology designed to treat autoimmune and allergic diseases by conjugating a target cytokine to a carrier protein, stimulating the patient's immune system to produce a sustained, polyclonal antibody response against the overproduced cytokine.

In therapeutics, Neovacs faces intense competition from approved biologics (e.g., anifrolumab in lupus, dupilumab in allergy) from large pharma. As an investor, it competes with venture capital and other holding companies for high-potential early-stage deals, where its operator experience is its key differentiator.